11
May 2026
Gastrolyzer® interpretation chart update
Included with every Gastrolyzer® range order, Bedfont® Scientific Limited provides practical resources designed to support and simplify hydrogen and methane breath testing (HMBT).
Stay Informed!
11
May 2026
Brain artery widening may drive lacunar stroke more than artery narrowing,
Abnormal brain artery widening is associated with lacunar stroke, indicating a shift in understanding the mechanisms behind small vessel disease in the brain.
11
May 2026
Endometriosis linked to slightly higher birth defect risk in infants
For babies born to people with endometriosis, there is a small but significant increased risk of congenital anomalies, often called birth defects, according to new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250439.
11
May 2026
Andes hantavirus outbreak highlights global spillover and transmission risks
A Virginia Tech disease ecologist said the outbreak of Andes hantavirus aboard the international MV Hondius cruise ship underscores how little scientists still know about the viruses circulating silently in wild rodent populations before they spill into humans.
11
May 2026
New obesity drugs may shift blame toward food industry
An essay presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) suggests that new age of obesity drugs could shift the blame for living with obesity from individuals to the food industry – just as smoking has been blamed on tobacco industry and to a lesser extent alcohol consumption on the alcohol industry.
11
May 2026
Longer working hours linked to rising obesity across OECD countries
A new study presented at this year's European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that a 1% reduction in annual working hours is associated with a 0.16% decrease in obesity rates across OECD countries.
11
May 2026
Semaglutide shows sustained weight loss benefits in older adults
A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .
11
May 2026
Eating out regularly linked to higher obesity risk worldwide
New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) suggests that no matter where people live, eating out instead of preparing meals at home is linked to weight gain and obesity.
11
May 2026
Daily orforglipron treatment reduces weight and blood sugar in seniors
A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.
11
May 2026
Prenatal progesterone exposure alters brain development genes in male fetuses
Excessive exposure to progesterone in the womb can alter a gene in the frontal cortex in male sheep fetuses, which is needed for brain development and function, according to research presented at the 28th European Congress of Endocrinology in Prague.
